Literature DB >> 16283165

Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.

Gareth L Thomas, Peter Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16283165     DOI： 10.1007/s00134-005-2848-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  7 in total

1.  Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.

Authors:  Esther B Bachli; Stephan R Vavricka; Roland B Walter; Monika I Leschinger; Marco Maggiorini
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

Review 2.  Activated protein C versus protein C in severe sepsis.

Authors:  S B Yan; J F Dhainaut
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Activated protein C for the treatment of fulminant meningococcal septicaemia.

Authors:  G L Thomas; T Wigmore; P Clark
Journal:  Anaesth Intensive Care       Date:  2004-04       Impact factor: 1.669

4.  Early treatment with activated protein C for meningococcal septic shock: case report and literature review.

Authors:  Tal Hasin; David Leibowitz; David Rot; Yoram Weiss; Tova Chajek-Shaul; Ran Nir-Paz
Journal:  Intensive Care Med       Date:  2005-05-20       Impact factor: 17.440

5.  Human recombinant activated protein C in meningococcal sepsis.

Authors:  Gregory Wcisel; David Joyce; Arna Gudmundsdottir; D Michael Shasby
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

6.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

Review 7.  Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.

Authors:  Pierre-François Laterre; Xavier Wittebole
Journal:  Crit Care       Date:  2003-06-30       Impact factor: 9.097
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.